In trading on Friday, shares of Nurix Therapeutics Inc (Symbol: NRIX) entered into oversold territory, hitting an RSI reading of 29.4, after changing hands as low as $14.50 per share. By ...

Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the sixteen ratings firms that are covering the stock, Marketbeat reports.

SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) is expected to announce its earnings results on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.67 ...

SAN FRANCISCO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of ...

The fireside chat will be webcast live and may be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event. About Nurix ...

Zymeworks Inc. (ZYME) shares soared 5.4% in the last trading session to close at $11.70. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

On April 5, 2023, Stefani A. Wolff notified Nurix Therapeutics (NRIX) of her decision to resign from her position as Chief ...

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a strong buy.